2m 2m 2m 2m 2m 2m 2m
Vertex Pharma (VRTX)
NASDAQ
$468.51+$1.72 (+0.37%)
Price as of Jun 23, 2026 4:07 PM EDT- $118.5BMarket Cap
- 5.24%1-Year Change
- BiotechnologyIndustry
Vertex Pharma (VRTX)
$468.51+$1.72 (+0.37%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 12.0B +8.63% | 11.0B +11.66% | 9.9B +10.51% | 8.9B +17.91% | |
Cost of Revenue | 1.7B +7.89% | 1.5B +21.26% | 1.3B +16.84% | 1.1B +19.48% | |
Gross Profit | 10.3B +8.74% | 9.5B +10.25% | 8.6B +9.64% | 7.9B +17.69% | |
Sales and Marketing Expense | 1.8B +19.72% | 1.5B +28.83% | 1.1B +20.31% | 944.7M +12.45% | |
Research and Development Expense | -3.9B +7.69% | -3.6B +14.78% | -3.2B +19.09% | -2.7B -12.96% | |
Depreciation and Amortization Expense | 209.8M +1.25% | 207.2M +14.29% | 181.3M +22.25% | 148.3M +18.07% | |
Total Operating Expenses | 7.8B -30.44% | 11.3B +86.39% | 6.0B +30.58% | 4.6B -3.53% | |
Operating Profit | 4.2B +1,891.88% | -232.9M -106.08% | 3.8B -11.04% | 4.3B +54.83% | |
Interest Income | 490.9M -17.92% | 598.1M -2.70% | 614.7M +325.10% | 144.6M +2,851.02% | |
Interest Expense | N/A N/A | N/A N/A | -44.1M -19.53% | -54.8M -10.89% | |
Interest Income and Expense and Net | 490.9M -17.92% | 598.1M +4.82% | 570.6M +535.41% | 89.8M +258.66% | |
Total Nonoperating Income and Expense | -7.7M -91.06% | -86.1M +277.63% | -22.8M -86.17% | -164.8M -3,463.27% | |
Income before Taxes | 4.6B +1,768.49% | 248.5M -94.33% | 4.4B +3.48% | 4.2B +55.01% | |
Income Taxes | 690.0M -12.00% | 784.1M +3.14% | 760.2M -16.50% | 910.4M +134.46% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 4.0B +838.09% | -535.6M -114.80% | 3.6B +8.96% | 3.3B +41.84% | |
Net Income from Continuing Operations Applicable to Common | 4.6B +1,768.49% | 248.5M -94.33% | 4.4B +3.48% | 4.2B +55.01% | |
Basic EPS and Net Income | 15.46 +843.27% | -2.08 -114.80% | 14.05 +8.33% | 12.97 +42.68% | |
Diluted EPS and Net Income | 15.32 +836.54% | -2.08 -114.97% | 13.89 +8.35% | 12.82 +42.29% | |
Basic Weighted Average Shares | 255.7M -0.85% | 257.9M +0.08% | 257.7M +0.62% | 256.1M -0.62% | |
Diluted Weighted Average Shares | 258.0M +0.04% | 257.9M -1.00% | 260.5M +0.54% | 259.1M -0.31% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 5.1B +11.27% | 4.6B -55.93% | 10.4B -1.28% | 10.5B +54.58% | |
Short-Term Investments | 1.5B -1.49% | 1.5B +82.09% | 849.2M +209.36% | 274.5M -62.39% | |
Cash and Cash Equivalents and Short-Term Investments | 6.6B +8.05% | 6.1B -45.48% | 11.2B +4.08% | 10.8B +43.24% | |
Total Current Assets | 11.2B +16.72% | 9.6B -32.15% | 14.1B +6.87% | 13.2B +38.43% | |
Accumulated Depreciation | 1.2B +13.08% | 1.1B -10.44% | 1.2B +15.73% | 1.0B +14.65% | |
Property and Plant and Equipment and Net | 1.5B +23.82% | 1.2B +5.91% | 1.2B +4.59% | 1.1B +1.31% | |
Total Long-Term Assets | 1.2B +23.75% | 999.3M +11.62% | 895.3M +71.58% | 521.8M +370.94% | |
Total Assets | 25.6B +13.80% | 22.5B -0.87% | 22.7B +25.23% | 18.2B +35.13% | |
Income Taxes Payable | 103.1M -36.00% | 161.1M +61.91% | 99.5M -19.30% | 123.3M -41.65% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 3.9B +8.32% | 3.6B +0.48% | 3.5B +29.37% | 2.7B +28.02% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.3B +40.77% | 901.8M +2.75% | 877.7M +27.98% | 685.8M +487.16% | |
Total Liabilities | 7.0B +13.94% | 6.1B +18.91% | 5.1B +21.51% | 4.2B +27.18% | |
Retained Earnings | 13.6B +41.15% | 9.6B -5.28% | 10.1B +55.49% | 6.5B +103.79% | |
Total Stockholders Equity | 18.7B +13.75% | 16.4B -6.66% | 17.6B +26.36% | 13.9B +37.75% | |
Total Shares Outstanding | 254.0M -1.15% | 256.9M -0.29% | 257.7M +0.27% | 257.0M +1.00% | |
Cash Flow | |||||
Cash from Operating Activities | 3.6B +837.19% | -492.6M -113.93% | 3.5B -14.35% | 4.1B +56.23% | |
Capital Expenditures | 437.6M +46.99% | 297.7M +48.55% | 200.4M -2.10% | 204.7M -12.89% | |
Cash from Investing Activities | -945.4M -74.92% | -3.8B +20.00% | -3.1B +878.42% | -321.1M -5.81% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -2.3B +51.27% | -1.5B +165.90% | -562.2M +730.43% | -67.7M -95.42% | |
Financials Ratio | |||||
Gross Margin | 86.21% +0.11% | 86.11% -1.26% | 87.21% -0.79% | 87.90% -0.18% | |
Operating Margin | 34.86% +1,749.61% | -2.11% -105.44% | 38.83% -19.50% | 48.23% +31.31% | |
Return on Assets | 16.41% +793.46% | -2.37% -113.36% | 17.71% -15.82% | 21.04% +13.10% | |
Return on Equity | 22.54% +815.25% | -3.15% -113.71% | 22.99% -16.92% | 27.67% +10.97% | |
Revenue Growth | 8.63% -26.04% | 11.66% +10.97% | 10.51% -41.31% | 17.91% -18.81% | |
Current Ratio | 2.90 +7.76% | 2.69 -32.48% | 3.99 -17.39% | 4.83 +8.14% | |
Cash Ratio | 1.32 +2.73% | 1.28 -56.14% | 2.92 -23.69% | 3.83 +20.75% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow